Neosoma Inc.

• Very low neuro-oncology volume sites
• Institutions requiring strictly on-premises processing without cloud options (on-prem options not provided in vendor public materials)
• Organizations requiring security certifications not documented by the vendor (e.g., ISO 27001) and unwilling to accept SOC 2 or equivalent as sufficient

• Brain Mets intended use constraints from the FDA 510(k) summary:
  • Semi-automatic segmentation of previously diagnosed brain metastases
  • Intended for adult population (22+)
  • Not intended for other brain lesion types

• The vendor indicates protocol tolerance for MRI sequences and suggests no protocol changes are required; prospective customers should validate performance across their scanner models and sequences.

Partner narratives reference potential future indications (for example, meningiomas or pediatric gliomas) as pipeline possibilities. These references are not to be interpreted as regulatory commitments and should be confirmed through vendor announcements and regulatory filings.

The vendor references Category III CPT codes (0865T and 0866T) as relevant for quantitative brain MRI analysis with comparison to prior studies. Category III codes are typically associated with emerging technologies; payer coverage and reimbursement amounts can be variable and require billing specialist review.

Vendor and partner communications include clinician quotes associated with FDA clearance milestones and partnership announcements. These are vendor- or partner-published statements and should be treated as curated testimonials rather than independent evaluations. Examples include paraphrased statements from clinical leaders accompanying FDA clearance announcements indicating the vendor’s clearances were notable for efficiency or objectivity in neuro-oncology imaging.

No consistent Neosoma-specific user reviews were identified on community platforms such as Reddit or Hacker News in the retrieved results. Discussion about auto-segmentation tools exists in professional forums, but direct user commentary on Neosoma installations was not located.

Based on product positioning and FDA-cleared indications, institutions may select Neosoma if they value:

• A platform focused on neuro-oncology workflow features rather than a general PACS add-on
• PACS integration combined with lesion tracking and export capabilities to planning systems
• Use of quantitative volumetric outputs that may map to current billing codes for quantitative brain MRI analysis

Innolitics published a case study describing how Neosoma pursued a modular regulatory strategy culminating in 510(k) clearance for Brain Mets, including process metrics presented by Innolitics.

Critical evaluation:

• This is a partner-authored narrative and may emphasize favorable outcomes. The FDA clearance is verifiable via FDA documentation, but process metrics described by the partner should be corroborated against primary documents where necessary.

Rook Quality Systems describes supporting Neosoma in pursuing 510(k) clearance for an HGG device.

Critical evaluation:

• Useful for understanding regulatory partnerships, but not an end-user outcomes study; it does not provide hospital-level ROI or efficiency measurements.

A distribution announcement describes Neosoma solutions connecting to the Nuance Precision Imaging Network.

Critical evaluation:

• Connection to a network can refer to different technical or commercial integration depths (listing vs. operational deployment). Buyers should clarify operational implications such as data routing, procurement channels, and support responsibilities.

Best fit likely:

• Mid-to-large hospitals and academic centers with substantial neuro-oncology MRI follow-up volume and multidisciplinary care pathways
• Clinical trial imaging programs via partner arrangements

• Neuro-oncology clinics (glioblastoma/high-grade gliomas)
• Radiation oncology / SRS programs treating brain metastases
• Neurosurgery programs requiring contour/planning integration
• Clinical trial imaging teams for neuro-oncology studies

• Decision makers: department chairs, radiology informatics leads, radiation oncology leadership, neuro-oncology program directors, CIO/CISO/vendor management
• End users: neuroradiologists, radiation oncologists, neurosurgeons, medical physicists/dosimetrists, research coordinators

• Need for standardized volumetrics and longitudinal lesion tracking
• Willingness to integrate a cloud SaMD into PACS workflows
• Sufficient scan volume to justify the vendor’s published per-study or per-volume pricing
• Requirement to export contours into planning systems to reduce manual contour workload